Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels

被引:55
作者
Fusco, Alessandra [1 ]
Miele, Luca [2 ]
D'Uonnolo, Annalisa [1 ]
Forgione, Alessandra [2 ]
Riccardi, Laura [2 ]
Cefalo, Consuelo [2 ]
Barini, Angela [3 ]
Bianchi, Antonio [1 ]
Giampietro, Antonella [1 ]
Cimino, Vincenzo [1 ]
Landolfi, Raffaele [2 ]
Grieco, Antonio [2 ]
De Marinis, Laura [1 ]
机构
[1] Catholic Univ, Div Endocrinol, Sch Med, I-00168 Rome, Italy
[2] Catholic Univ, Inst Internal Med, Sch Med, I-00168 Rome, Italy
[3] Catholic Univ, Inst Biochem & Clin Biochem, Sch Med, I-00168 Rome, Italy
关键词
HORMONE-BINDING-PROTEIN; PLACEBO-CONTROLLED TRIAL; ABDOMINAL VISCERAL FAT; GROWTH-FACTOR-I; INSULIN-RESISTANCE; WEIGHT-REDUCTION; OBESE SUBJECTS; SERUM LEVELS; FULL-LENGTH; SHORT-TERM;
D O I
10.1111/j.1365-2265.2011.04291.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Nonalcoholic fatty liver disease (NAFLD) has been described in adult GH deficiency syndrome. Furthermore, chronic liver disease can be associated with significant changes in levels of IGF-I, GH-binding protein (GHBP), IGF-binding proteins (IGFBPs) and acid-labile subunit (ALS). However, the effect of liver steatosis on the GHBP production has not been investigated yet. Aim of the study To explore whether GH secretion and/or levels of IGF-I, IGFBP-3, ALS and GHBP could be altered in obese patients in relation to the presence of liver steatosis. Materials and methods A total of 115 obese patients (BMI > 30) were enrolled in the protocol (65 patients with liver steatosis and 50 age- and BMI-matched controls). In all patients, the following parameters were studied: serum levels of glucose, insulin, the HOMA index, IGF-I, GHBP, IGFBP-3, ALS and GH after GHRH and arginine stimulation test. Results As expected, patients with NAFLD had blood glucose, insulin, HOMA-R significantly higher than controls, indicating a more severe insulin-resistance state in NAFLD. Furthermore, patients with NAFLD had higher levels of GHBP and IGFBP-3 and lower GH peak and IGF-I levels as compared to controls. No difference was found in ALS levels between the groups. In a multivariate analysis, GHBP was positively associated with hepatic steatosis while IGF-1 was negatively associated with hepatic steatosis. Conclusions This study demonstrates that in patients with NAFLD, the GHBP levels are increased, and that the GH/IGF-I axis is significantly altered probably leading to reduced IGF-I bioavailability at tissue level.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 36 条
  • [11] THE DAWN PHENOMENON IS RELATED TO OVERNIGHT GROWTH-HORMONE RELEASE IN ADOLESCENT DIABETICS
    EDGE, JA
    MATTHEWS, DR
    DUNGER, DB
    [J]. CLINICAL ENDOCRINOLOGY, 1990, 33 (06) : 729 - 737
  • [12] Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid Metabolism
    Fan, Yong
    Menon, Ram K.
    Cohen, Pinchas
    Hwang, David
    Clemens, Thomas
    DiGirolamo, Douglas J.
    Kopchick, John J.
    Le Roith, Derek
    Trucco, Massimo
    Sperling, Mark A.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (30) : 19937 - 19944
  • [13] Insulin sensitivity and secretion influence the relationship between growth hormone-binding-protein and leptin
    Fernandez-Real, JM
    Granada, ML
    Ruzafa, A
    Casamitjana, R
    Ricart, W
    [J]. CLINICAL ENDOCRINOLOGY, 2000, 52 (02) : 159 - 164
  • [14] Growth hormone (GH) substitution for one year normalizes elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial
    Fisker, S
    Vahl, N
    Hansen, TB
    Jorgensen, JOL
    Hagen, C
    Orskov, H
    Christiansen, JS
    [J]. GROWTH HORMONE & IGF RESEARCH, 1998, 8 (02) : 105 - 112
  • [15] Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity:: A 12-month placebo-controlled trial
    Franco, C
    Brandberg, J
    Lönn, L
    Andersson, B
    Bengtsson, BÅ
    Johannsson, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) : 1466 - 1474
  • [16] Metabolic Parameters and Nonalcoholic Fatty Liver Disease in Hypopituitary Men
    Hong, J. W.
    Kim, J. Y.
    Kim, Y. -E.
    Lee, E. J.
    [J]. HORMONE AND METABOLIC RESEARCH, 2011, 43 (01) : 48 - 54
  • [17] Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease
    Ichikawa, Tatsuki
    Nakao, Kazuhiko
    Hamasaki, Keisuke
    Furukawa, Ryuji
    Tsuruta, Shotarou
    Ueda, Yasuo
    Taura, Naota
    Shibata, Hidetaka
    Fujimoto, Masumi
    Toriyama, Kan
    Eguchi, Katsumi
    [J]. HEPATOLOGY INTERNATIONAL, 2007, 1 (02) : 287 - 294
  • [18] ACIPIMOX POTENTIATES GROWTH-HORMONE (GH) RESPONSE TO GH-RELEASING HORMONE WITH OR WITHOUT PYRIDOSTIGMINE BY LOWERING SERUM-FREE FATTY-ACID IN NORMAL AND OBESE SUBJECTS
    LEE, EJ
    NAM, SY
    KIM, KR
    LEE, HC
    CHO, JH
    NAM, MS
    SONG, YD
    LIM, SK
    HUH, KB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (08) : 2495 - 2498
  • [19] Insulin regulation of human hepatic growth hormone receptors: Divergent effects on biosynthesis and surface translocation
    Leung, KC
    Doyle, N
    Ballesteros, M
    Waters, MJ
    Ho, KKY
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) : 4712 - 4720
  • [20] SERUM LEVELS OF GROWTH HORMONE-BINDING PROTEIN AND INSULIN-LIKE GROWTH FACTOR-I DURING PUBERTY
    MASSA, G
    BOUILLON, R
    VANDERSCHUERENLODEWEYCKX, M
    [J]. CLINICAL ENDOCRINOLOGY, 1992, 37 (02) : 175 - 180